Follow us on LinkedIn
NTC España website
NTC
Novelty, Technology, Care
Interview by Riccardo Carbucicchio, CEO for Life Science Review
- Nov 6, 2024
In the interview with Life Science Review, NTC CEO Riccardo Carbucicchio highlighted NTC's commitment to producing drugs that fill patients' unmet medical needs...
NTC grants Chinoin the license and distribution rights in Mexico and LatAm for its innovative therapeutic solution for colonoscopy preparation
- Oct 24, 2024
The deal represents an important step for the internationalization of NTC015, developed to address unmet medical needs and improve patient compliance.
NTC launches Imperial, the new eye drops product line on THE PATIENT’S SIDE
- Oct 7, 2024
NTC, an international pharmaceutical company headquartered in Milan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems
Cataract surgery: the fixed-dose combination of an antibiotic with an anti-inflammatory drug in eye drops is currently available in 50 countries worldwide
- Sep 24, 2024
The combination has been registered in nearly 60 countries for the prevention and treatment of inflammation and the prevention of infection associated with cataract surgery in adults. It is currently marketed in 50 countries worldwide.
PHARMACOVIGILANCE